GlassScriptPhysician profile
David M Band
NPI 1043316094
$947.20
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $201 · 2021: $50.64 · 2022: $29.15.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $317.05 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $200.34 | 2019-2020 | |
| Lundbeck LLC | $66.09 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.77 | 2019-2020 | |
| Shire North American Group INC | $55.28 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $44.78 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $44.77 | 2019 | |
| Allergan, INC. | $42.86 | 2019-2020 | |
| Tris Pharma INC | $38.49 | 2019 | |
| Supernus Pharmaceuticals, INC. | $20.13 | 2021 | |
| Vanda Pharmaceuticals INC. | $18.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.13 | 2019 | |
| Neurocrine Biosciences, INC. | $14.89 | 2019 | |
| Neuronetics, INC. | $13.30 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Band listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.